Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Matsumotokiyoshi: Record-high Sales of \256 Bil., Profits of \6.6 Bil. Posted
June 17, 2002
- Eli Lilly's Teriparatide Effective against Severe Osteoporosis
June 17, 2002
- 94 Drugs in Development for Children: PhRMA Survey
June 17, 2002
- BULLETIN
June 17, 2002
- Ohki: Consolidated Sales Increase by 4.1% to \69.7 Bil.
June 17, 2002
- Clinical Trial Results for Eli Lilly's New ED Drug Reported
June 17, 2002
- Shionogi: Net Profits Plummet 33% Due to Restructuring
June 10, 2002
- Kyowa Hakko: Drug Sales Up 0.6% to \142.2 Bil.
June 10, 2002
- Korosho to Accelerate Approval of Overseas Anticancer Agents
June 10, 2002
- Chugai: Sales Up 6.7% Due to Good Performance of Mainstays
June 10, 2002
- Kuraya Sanseido: Sales, Profits Sharply Up Due to Cost Cutting
June 10, 2002
- Time Is Running Out for Passage of Healthcare Reform Bills
June 10, 2002
- Dainippon: Sales, Profits Up 3 Years in a Row
June 10, 2002
- Suzuken: Consolidated Sales Up to \955.7 Bil.
June 10, 2002
- Revised Forecasts of Social Security Benefits Released
June 10, 2002
- Takeda: Becomes 1st Japanese Drug House with Sales of Over \1 Trillion
June 10, 2002
- Azwell: Operating Profits Return to Black
June 10, 2002
- Model Curriculum for Pharmacists Drafted by PSJ
June 10, 2002
- Sankyo: Overseas Sales Make Up for Japan's Weak Sales, but Profits Down
June 10, 2002
- Fukujin: Sales Up 9.5% to \455 Bil.
June 10, 2002
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…